How Insiders and Institutions are Trading Diplomat Pharmacy, Inc. (DPLO)

Marco Green
November 18, 2017

Lombard Odier Asset Management (Usa) accumulated 0.1% or 30,000 shares. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The stock appeared $10.97 above its 52-week highs and is up 0.69% for the last five trades. Mizuho increased their price objective on shares of Diplomat Pharmacy from $16.00 to $20.00 and gave the stock a neutral rating in a report on Tuesday, November 7th. In the past 3-month period alone, shares of DPLO have appreciated -1.94 - or -11.71%. The firm's revenue was down 4.8% on a year-over-year basis. equities research analysts predict that Diplomat Pharmacy, Inc. will post 0.85 earnings per share for the current fiscal year. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 40.48% since November 17, 2016 and is downtrending. 96,522 are held by Kayne Anderson Rudnick Investment Mgmt Ltd Company. Walleye Trading Lc invested in 460,569 shares or 0.06% of the stock. Diplomat Pharmacy, Inc. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34. Ahl Prns Limited Liability Partnership stated it has 59,290 shares or 0.02% of all its holdings. Tudor Corp Et Al holds 0.86% of its portfolio in Tribal Group plc (LON:TRB) for 695,920 shares.

Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The company maintains price to book ratio of 1.50 industry average at 1.95.

The specialty pharmacy said on Wednesday that it would buy Missouri-based pharmacy benefit manager LDI Integrated Pharmacy Services for $388 mln in cash and $80 mln in stock. It has a 164.85 P/E ratio. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Shares of Diplomat Pharmacy Inc (NYSE:DPLO) now have an Average Brokerage Recommendation of 2.42, number of Recs in ABR is 11 while industry rank of the company by ABR is 233 out of 265. They expect $0.16 EPS, up 100.00% or $0.08 from last year's $0.08 per share. DPLO's profit will be $11.40 million for 28.72 P/E if the $0.16 EPS becomes a reality. Art Ltd Liability Corporation owns 0.04% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 54,441 shares. The average investment rating for DPLO on a scale of 1 to 5 (1 being a strong sell and 5 being a strong buy) is a 3.58 or a Hold. Therefore 25% are positive. The stock now has an average rating of Hold and a consensus price target of $19.39. Tribal Group PLC had 9 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Tuesday, November 7 with "Hold". The stock of Diplomat Pharmacy Inc (NYSE:DPLO) has "Buy" rating given on Friday, October 27 by Robert W. Baird. The rating was initiated by Cowen & Co on Friday, June 24 with "Market Perform". Citigroup Inc. lowered Diplomat Pharmacy to a "market perform" rating in a report on Thursday, November 3rd. BidaskClub upgraded Diplomat Pharmacy from a hold rating to a buy rating in a research note on Tuesday, September 26th. The most optimistic analyst sees the stock reaching $24 while the most conventional has $11 target price. The firm earned "Neutral" rating on Thursday, November 16 by Robert W. Baird. Avondale Partners lowered Diplomat Pharmacy from an "outperform" rating to a "market perform" rating in a report on Thursday, November 3rd.

Analysts await Theravance Biopharma Inc (NASDAQ:TBPH) to report earnings on February, 26.

Insider Trading Activity for Diplomat Pharmacy, Inc. Analysts have a mean recommendation of 3.30 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).

Other reports by Click Lancashire

Discuss This Article